Homology Medicines Earning Date (FIXX)

USA |NASDAQ |USD

FIXX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.54
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $2.19M

Homology Medicines's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

FIXX Earnings Date & History Chart

FIXX Earnings & Revenue Forecast

FIXX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $-2.40 $-3.00 $-1.98

FIXX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-2.40 $-2.40 $-2.44

FIXX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 9 $2.94M $0.00 $8.70M

FIXX Earnings Date & Revenue History

FIXX Earnings History

|
Show More
Show More

FIXX Revenue History

|
Show More
Show More

Homology Medicines Next Earnings Date & Report

FIXX Next Earnings Date & Report Preview: Jun 2022 (FQ)

FIXX's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Homology Medicines Previous Earnings Dates & Reports

FIXX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Homology Medicines's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.

FIXX Previous Earnings Date & Report Recap: Dec 2020 (FY)

Homology Medicines's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.

FIXX's earnings per share (EPS) was $-2.80, beating the consensus analysts forecast of $-2.89 by -3.11% , and lower than the previous year's EPS (Dec 2019) by 13.36%.

Revenues were $2.70M, worse than the forecast of $2.84M by -4.86%, and up by 62.18% from previous year's revenue.

The company reported a net income of $-128.69M.

Homology Medicines reported a free cash flow of $-98.06M for its fiscal year, compared to $-113.19M a year ago.

The company ended the fiscal year with $15.44M in total debt. lala